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Key Points
Hematopoietic stem/progenitor mutation burden is not increased in SCN.
Clonal hematopoiesis due to mutations of TP53 is present in the majority of patients with SDS.
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Severe congenital neutropenia (SCN) and Shwachman-Diamond syndrome (SDS) are congenital
neutropenia syndromes with a high rate of leukemic transformation. Hematopoietic stressors may
contribute to leukemic transformation by increasing the mutation rate in hematopoietic stem/progenitor
cells (HSPCs) and/or by promoting clonal hematopoiesis. We sequenced the exome of individual
hematopoietic colonies derived from 13 patients with congenital neutropenia to measure total mutation
burden and performed error-corrected sequencing on a panel of 46 genes on 80 patients with congenital
neutropenia to assess for clonal hematopoiesis. An average of 3.6 ± 1.2 somatic mutations per exome was
identified in HSPCs from patients with SCN compared with 3.9 ± 0.4 for healthy controls (P = NS). Clonal
hematopoiesis due to mutations in TP53 was present in 48% (13/27) of patients with SDS but was not seen
in healthy controls (0/17, P < .001) or patients with SCN (0/40, P < .001). Our SDS cohort was young
(median age 6.3 years), and many of the patients had multiple TP53 mutations. Conversely, clonal
hematopoiesis due to mutations of CSF3R was present in patients with SCN but was not detected in
healthy controls or patients with SDS. These data show that hematopoietic stress, including granulocyte
colony-stimulating factor, do not increase the mutation burden in HSPCs in congenital neutropenia. Rather,
distinct hematopoietic stressors result in the selective expansion of HSPCs carrying specific gene
mutations. In particular, in SDS there is enormous selective pressure to expand TP53-mutated HSPCs,
suggesting that acquisition of TP53 mutations is an early, likely initiating event, in the transformation to
myelodysplastic syndrome/acute myeloid leukemia in patients with SDS.
Introduction
Severe congenital neutropenia (SCN) is a rare syndrome characterized by chronic neutropenia present
from birth and by recurring bacterial infections. Mutations of ELANE are the most common cause of SCN,
accounting for ∼50% of cases, with mutations of HAX1 and G6PC3 accounting for an additional 10% to
20% of cases.  Treatment with granulocyte colony-stimulating factor (G-CSF) is the standard of care for
SCN, because it increases the level of circulating neutrophils and reduces infection-related mortality.
Shwachman-Diamond syndrome (SDS) is a recessive disorder characterized by exocrine pancreatic
insufficiency, bone marrow dysfunction, and skeletal abnormalities. SDS is caused in most cases by
biallelic mutations of SBDS.  Current studies support a model of disease pathogenesis in which SBDS
mutations lead to impaired ribosome assembly.
A shared feature of SCN, SDS, and several other bone marrow failure syndromes that feature neutropenia
is a marked propensity to develop a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
The cumulative incidence of MDS/AML in patients with SCN treated with G-CSF is 22%.  Of note,
MDS/AML has been reported in SCN secondary to ELANE, HAX1, G6PC3, or WAS mutations.  The
cumulative incidence of MDS/AML in SDS is ∼20%.  Acquired gain-of-function mutations of CSF3R,
encoding the G-CSF receptor, are present in ∼40% of cases of SCN and are associated with the
development of MDS/AML.  Mutations of RUNX1 are present in ∼65% of patients with SCN who
develop AML/MDS.  In SDS, a recent study showed that mutations of TP53 are common in MDS that
develops in patients with SDS.  Whether the TP53 mutations represent an early, leukemia initiating event,
or a late progression event (as has been shown for some types of secondary AML),  is unknown. Despite
these observations, the molecular mechanisms contributing to transformation to MDS/AML in congenital
neutropenia syndromes are poorly understood, limiting the development of new therapies or strategies for
risk stratification or early detection.
The accumulation of mutations in hematopoietic stem cells (HSCs) with age results in the production of a
genetically heterogeneous cell population, with each HSC possessing its own unique set of private
mutations.  HSCs that acquire somatic mutations that confer a competitive fitness advantage relative to
their normal counterparts may clonally expand. Indeed, several groups have documented the presence of
clonal hematopoiesis in healthy individuals.  Factors that increase the rate at which mutations
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accumulate in HSCs may increase the frequency of clonal hematopoiesis and ultimately MDS/AML. The
common mutations causing SCN are not known to be directly involved in DNA repair, suggesting the
possibility that noncell autonomous mechanisms may contribute to the high rate of leukemic
transformation. For example, G-CSF expression is induced by neutropenia and may increase the rate at
which HSCs accumulate mutations by inducing their replication.  Of note, prior studies have
demonstrated that the G-CSF receptor (CSF3R) is expressed on HSCs.  Factors that select for HSCs
carrying deleterious mutations also may increase the risk of MDS/AML. For example, we previously
showed that HSCs carrying mutations in TP53 are selected by exposure to chemotherapy.  Thus, it is
possible that HSC-cell autonomous and/or noncell autonomous alterations in congenital neutropenia may
confer a competitive fitness advantage to HSCs that carry leukemia-associated mutations. To test these
possibilities, we measured the mutation burden in individual hematopoietic stem/progenitor cells (HSPCs)
and characterized clonal hematopoiesis in patients with congenital neutropenia.
Methods
Human subjects
A total of 101 human blood or bone marrow samples were obtained for our study. These samples were
divided into 5 cohorts: patients with SCN (40), patients with SDS (28), patients with cyclic neutropenia
(13), healthy volunteers (17), and cord blood (3). Coded blood or bone marrow samples from patients with
congenital neutropenia were obtained from the Severe Chronic Neutropenia International Registry
(https://depts-washington-edu.medproxy.hofstra.edu/registry/), the SDS Registry (http://sdsregistry.org), or
from various other academic institutions. Anonymized cord blood samples were obtained from the Saint
Louis Cord Blood Bank (http://www.slcbb.org). Coded blood or bone marrow samples were obtained from
healthy volunteers, with the following exclusion criteria: a personal history of cancer, the use of cytotoxic
drugs for nonmalignant disease, a history of radiation therapy, or known infections with hepatitis B or C,
human T-cell leukemia virus, or HIV. In each case, the banking and distribution of these samples were
approved by institutional review boards at the involved institution; written informed consent was obtained
from all participants.
Hematopoietic progenitor cell expansion
The low-density mononuclear cell fraction was isolated from peripheral blood or bone marrow by
centrifugation at 400g for 30 minutes over a Histopaque 1077 gradient (Sigma); in some cases, red blood
cells were lysed by incubating in Tris-buffered ammonium chloride (pH 7.4). An aliquot (1 × 10 ) of
unselected mononuclear cells was removed, and genomic DNA was prepared using the QIAmp DNA Mini
kit (Qiagen), per the manufacturer’s instructions. The remainder of the cells was stained with a panel of
fluorescein-conjugated lineage markers (CD3, CD19, CD14, and CD16), phycoerythrin-conjugated CD34,
and allophycocyanin-conjugated CD38. CD34  CD38  lineage  cells were sorted at 1 cell per well into a
96-well plate using a Cytomation MoFlow or Sony Synergy cell sorter. Prior to sorting, the 96-well plate
was seeded with irradiated (2000 cGy) AFT024 stromal cells (ATCC: SCRC-1007) at a density of 2.5 ×
10  cell per well. CD34  CD38  lineage  cells were cultured for 2 to 3 weeks in Iscove’s Modified
Dulbecco’s medium supplemented with 10% fetal calf serum, 1 mM  -glutamine, and the following
human recombinant cytokines: stem cell factor (10 ng/mL), FLT3 ligand (25 ng/mL), thrombopoietin (20
ng/mL), interleukin-3 (10 ng/mL), and G-CSF (10 ng/mL). The cultures were maintained at 37°C with 5%
CO  and ambient oxygen and supplemented with fresh media every 5 days. After 2 to 3 weeks of culture,
wells with visible hematopoietic cell growth were expanded into a 24-well plate without AFT024 feeder
cells for another week. Hematopoietic cells from the colonies were then harvested and counted and
genomic DNA was prepared using the Qiagen QIAmp DNA Micro Kit (Qiagen).
HSPC clone whole exome sequencing and variant calling
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Genomic DNA was fragmented, and exome capture was performed using a customized version of the
Agilent SureSelect Human All Exon v2 kit, which targets 99.01% of CCDS exons, 93.29% of RefSeq
genes, and 90% of known microRNA genes (MiRbase 14). Median sequence coverage was 104X (range
46.2-232X). Sequence was aligned to reference sequence build GRCh37-lite-build37, as previously
described.  Putative somatic mutations were identified via direct pairwise comparisons of each HSPC
clone to the unfractionated total peripheral blood/bone marrow cells from which it was derived. Single
nucleotide variants (SNVs) and insertions/deletions (Indels) were detected as previously described.
SNVs and Indels that exceeded 0.1% frequency in the 1000 genomes or National Heart, Lung, and Blood
Institute exome sequencing projects were removed. To remove nonclonal events, reference and variant
read counts were compared with a binomial distribution of the same number of reads, assuming a variant
allele frequency of 50%. Sites that significantly differed (Fisher’s exact test, P > .05) from the expected
binomial distribution were removed. Additional filters required the number of reference reads in the
control sample to be >30, the number of variant reads in the HSPC clone sample to be >5, and the variant
allele frequency in the control sample to be <3%. Finally, sites were manually reviewed to remove other
classes of alignment artifacts.
Error-corrected (Haloplex) targeted sequencing and variant detection
Error-corrected sequencing was performed using the Agilent Haloplex HS Target Enrichment System, as
previously described.  A customized HaloPlex HS Target Enrichment assay targeting 46 genes mutated in
clonal hematopoiesis and/or MDS/AML (supplemental Table 1, available on the Blood Web site) was
designed using the Agilent SureDesign platform. The probes had dual indices: a unique molecular barcode
to allow for error-corrected sequencing and a sample index to allow for sample multiplexing. Genomic
DNA (500 ng) was hybridized to the custom probes, ligated, captured with streptavidin, and polymerase
chain reaction amplified (×24 cycles) to create read families each with its own molecular bar code. Median
sequence coverage was 17 824X (range 9491-34 895). Variants were required to be supported by 3 read
families. Filters were applied to remove artifacts appearing at homopolymer runs of length >4 and
alignment artifacts appearing in >5% of a panel of normal samples. Next, background noise calculation
was performed on a position-by-position basis for each identified variant as follows: For each variant, read
counts were gathered from all other samples, excluding those sites with variant allele frequency >25%,
which were assumed to be germ line SNPs. In a single case (SCN51), we retained a truncation CSF3R
mutation with a variant allele frequency of 39%. A P value was obtained via Fisher's exact test, comparing
the reference and variant reads at a site to the number of reference and variant reads at that site in all other
samples. Multiple testing correction was applied with the P value adjust function (default parameters).
Those variants with an adjusted P value of <.1 were retained. The same process is repeated with
subsequent background calculations excluding all variants retained in previous rounds until no new
variants were identified. Finally, we interrogated the Exome Aggregation Consortium database
(http://exac.broadinstitute.org) to remove variants with an adjusted allele frequency <0.0005. Following
manual review, we reported somatic variants that generated missense, nonsense, or splice site mutations.
Statistical analysis
Continuous and count variables are described with means and standard deviations when distributions
appear symmetrical and by medians when the distributions appear skewed. Categorical variables are
described by percentages. Pearson correlations are used when the distributions of variables appear
symmetrical and Spearman correlations when they appear asymmetrical or there are outlying values that
would inflate a Pearson correlation. Independence between dichotomous variables in 2-way tables is
evaluated with Fisher’s exact tests, whereas exact χ  tests are used in 2-way tables with small sample sizes
where one or both variables are not dichotomous. Independent-sample Student t tests are used to compare
2 groups with respect to symmetrically distributed continuous variables. Analysis of covariance is used as
an alternative to analysis of variance in order to adjust for confounding variables such as age. The Kruskal-
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Wallis nonparametric alternative to analysis of variance is used when there are multiple groups and the
dependent variable is asymmetric. The analysis is followed by Bonferroni-adjusted pairwise Wilcoxon
tests. Logistic regression is used when the dependent variable is dichotomous with results reported as odds
ratios with 95% confidence intervals. For all tests, a P value <.05 was used to indicate statistical
significance. Statistical analyses were done with SAS Version 9.4 for Windows and the R statistical
package.
Results
Hematopoietic progenitor mutation burden
To determine whether chronic neutropenia and/or long-term treatment with G-CSF increased mutation
burden in hematopoietic progenitors, we sequenced the exomes of individual, ex vivo expanded HSPCs
from patients with congenital neutropenia (Figure 1A). These sequences were compared with the exome
sequence of total leukocytes from the same patient to identify clonal somatic mutations (see “Methods”).
Whereas we were successful in generating hematopoietic colonies of sufficient size for exome sequencing
from the majority of SCN, healthy donors, and cord blood samples, only 2 of 15 (13.3%) SDS samples
generated such colonies. This is consistent with a study showing that HSPCs from patients with SDS have
impaired growth.  In total, we sequenced hematopoietic colonies from 11 patients with SCN, 2 with SDS,
6 healthy donors, and 3 umbilical cord blood samples; patients with evidence of MDS or AML at the time
of tissue collection were excluded (Table 1; supplemental Tables 2 and 3). All of the patients with SCN for
whom information was available carried heterozygous germ line mutations of ELANE and were being
treated chronically with G-CSF. Of note, the 2 patients with SDS were younger than those in the SCN
cohort and had not received prior G-CSF treatment.
Across all samples, the number of genic somatic mutations detected in the progeny of each HSPC ranged
from 0 to 10 (Figure 1B; supplemental Table 4). As reported previously, a strong correlation between
HSPC mutation burden and the age of the patient was observed (Pearson r = 0.83, P < .001) (Figure 1C).
The lowest number of mutations was present in the cord blood samples, with only 1.4 ± 0.29 mutations per
HSPC exome (Figure 1D). The number of mutations detected in the exomes of HSPCs from healthy
donors (3.9 ± 0.38) is similar to that observed from patients with SCN (3.6 ± 1.2) or SDS (1.8 ± 0.65).
After adjusting for age, there was no difference in HSPC mutation burden in the different cohorts (P = .34
by analysis of covariance). Somatic copy number alterations were not identified in any of the
hematopoietic colonies (data not shown). These data suggest that the rate at which mutations accumulate
in HSPCs in patients with congenital neutropenia is not increased compared with that of healthy
individuals.
Clonal hematopoiesis
We used a sensitive error-corrected sequencing approach to look for clonal hematopoiesis in the blood or
bone marrow of patients with congenital neutropenia. Using this sequencing technique, we were able to
reliably detect mutations with a variant allele frequency of at least 0.1%, corresponding to 1 cell in 500
carrying a mutation. We interrogated 46 genes that have been reported to be mutated in individuals with
clonal hematopoiesis or MDS/AML (supplemental Table 1). We analyzed 17 healthy individuals, 40 with
SCN, and 27 with SDS (Table 2; supplemental Tables 2 and 3). We also analyzed 13 patients with cyclic
neutropenia. Cyclic neutropenia is characterized by intermittent neutropenia and is caused, in most cases,
by mutations of ELANE. However, in contrast to SCN, it rarely transforms to MDS/AML.  All of the
patients with cyclic neutropenia or SCN (for whom information was available) carried heterozygous germ
line mutations of ELANE, and all of the patients with SDS carried biallelic germ line mutations of SBDS.
As expected, the baseline (pre-G-CSF treatment) absolute neutrophil count (ANC) was significantly lower
in patients with SCN compared with patients with SDS or cyclic neutropenia (P < .001 and P < .01,
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respectively, using Bonferroni-corrected Wilcoxon tests). All of the patients with cyclic neutropenia or
SCN (for whom information was available) were treated chronically with G-CSF, compared with 10 of 25
(40%) cases of SDS (for which information was available). Ten of 40 patients (25%) of patients with SCN
underwent allogenic stem cell transplantation, compared with a single patient with cyclic neutropenia, and
1 patient with SDS. Only 2 patients with SCN in our cohort are known to have developed AML or MDS.
Clonal hematopoiesis due to any mutation was identified in 5 of 17 (29%) healthy individuals, 5 of 13
(38%) patients with cyclic neutropenia, 25 of 40 (62%) SCN cases, and 16 of 27 (59%) of SDS cases (P =
.08 by Pearson χ  of independence) (Figure 2A; supplemental Table 5). No consistent effect of tissue
origin (ie, blood vs bone marrow) was observed on the incidence of clonal hematopoiesis (supplemental
Figure 1A). Although clonal hematopoiesis was not detected in the 3 cord blood samples tested, we
observed no difference in the median age of individuals with or without clonal hematopoiesis, which may
reflect the rather narrow age range of cases analyzed in this study (Figure 2B).
Clonal hematopoiesis with CSF3R mutations
Consistent with prior reports,  clonal hematopoiesis due to mutations of CSF3R was detected in 40%
(16 of 40) of patients with SCN, compared with 0 of 17 of healthy controls (Fisher’s exact test, P = .003; 
Figure 2C). CSF3R mutations were detected in a single patient with cyclic neutropenia (1/17, 7.7%, P =
.04) and in no patients with SDS (0/27; P < .001). Of note, after removing CSF3R mutations, the
percentage of cases with clonal hematopoiesis was similar between healthy controls and patients with SCN
(Figure 2D). The size of the hematopoietic clone carrying a CSF3R mutation ranged from 0.26% to 78% of
cells in the blood samples (median 0.70%). The number of CSF3R mutations per patient with SCN ranged
from 0 to 3 (Figure 2E). Consistent with prior reports, all of the CSF3R variants are nonsense mutations
that truncate the cytoplasmic domain of the G-CSF receptor (Figure 2F). Logistic regression, both adjusted
for age and unadjusted, showed that the presence of CSF3R mutations was not related to standard
measures of disease severity in SCN, including baseline ANC or median dose of G-CSF (Figure 2G-H).
Clonal hematopoiesis with TP53 mutations
Clonal hematopoiesis due to mutations of TP53 was observed in 48% (13/27) of patients with SDS, but
was not detected in 17 healthy donors (P < .001 by Fisher’s exact test; Figure 3A). No mutations of TP53
were detected in any of the patients with SCN (0/40, P < .001) or cyclic neutropenia (0/13, P = .003).
TP53 mutations were detected at similar frequency in blood and bone marrow samples from patients with
SDS (supplemental Figure 1B). After removing TP53 mutations, the percentage of cases with clonal
hematopoiesis was similar between healthy controls and patients with SDS (Figure 3B). A significant
relationship between the presence of TP53 mutations and age was observed with an odds ratio of 1.53
(95% confidence interval: 1.12-2.09, P < .01) (Figure 3C). Remarkably, 80% (8/10) of patients ≥10 years
of age had at least 1 TP53 mutation, including 1 patient with 8 different TP53 mutations. The TP53
mutations were present in a low percentage of bone marrow cells (median 0.76%, range 0.1% to 7.7%).
For 1 case (SDS34), multiple bone marrow samples were analyzed and showed that an R249Q TP53
mutation not detected at age 4 was present at a variant allele fraction of 1.1% at age 6.2 years, with an
increase to 3.2% 1 month later (Figure 3D). The TP53 mutations clustered in the DNA binding domain of
the gene, and all were present in the International Agency of Research on Cancer TP53 Database (
Figure 3E). Logistic regression after adjusting for age showed that the presence of TP53 mutations was not
related to the degree of neutropenia, G-CSF treatment, or presence of anemia or thrombocytopenia (
Figure 3F-H and data not shown).
Discussion
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In this report, we show that the mutation burden in HSPCs from patients with SCN is comparable to that of
age-matched healthy individuals. Because of the limited number of SDS samples analyzed, firm
conclusions about mutation burden in SDS HSPCs are not possible. Nonetheless, these data suggest that an
elevated mutation rate in HSPCs is not solely responsible for the marked increased risk of MDS/AML in
congenital neutropenia. Although the published data are limited, this conclusion is supported by reports
showing that the overall mutation burden in MDS or AML arising in the setting of SCN or SDS is
comparable to that of de novo MDS/AML.
Here, we provide evidence for the selective expansion of HSPCs carrying specific gene mutations in
congenital neutropenia. In SDS, nearly 50% of patients have clonal hematopoiesis because of mutations of
TP53. Multiple TP53 mutations per patient were often detected. Of note, the variant allele frequencies of
the TP53 mutations in a given patient often varied considerably. For example, in patient SDS31, in whom
8 different TP53 mutations were identified, the variant allele frequency ranged from 0.12% to 3.0%.
Although single-cell genotyping is needed to confirm, this observation suggests that in patients with
multiple TP53 mutations, the mutations likely arose in distinct HSPCs. The frequency of TP53 mutations
increases with age in patients with SDS and was not seen in any patients with SCN or cyclic neutropenia,
or healthy controls. These observations show that specific stressors are present in SDS that strongly and
specifically select for HSPCs carrying TP53 mutations.
Mutations of SBDS that are present in the great majority of cases of SDS result in impaired ribosome
biogenesis.  There is evidence that ribosome biogenesis stress induces p53 expression, which in turn
results in growth arrest. For example, mutations in genes encoding for ribosomal proteins RPS19 in
Diamond-Blackfan syndrome or RPS14 in 5q  syndrome result in impaired ribosome biogenesis and
induction of TP53 expression in erythroid progenitors.  Importantly, genetic or pharmacologic
inhibition of p53 rescues the defect in erythropoiesis in RPS19-deficient cells, establishing the importance
of increased TP53 expression in these disorders.  Increased p53 expression also has been identified in
hematopoietic cells from patients with SDS or in Sbds-deficient murine hematopoietic cells.
Moreover, in mice with targeted disruption of Sbds in pancreatic cells, genetic ablation of Trp53 rescues
the severe atrophy in pancreatic acinar cells.  Together, these observations suggest a model in which
elevated p53 expression due to ribosome biogenesis stress in SDS HSPCs results in impaired HSPC
growth and/or survival. Mutations of TP53 in HSPCs are predicted to attenuate this growth arrest, resulting
in their selective expansion in patients with SDS. Our data suggest that the acquisition of TP53 mutations
is an early, initiating event, for the transformation to MDS/AML in SDS patients. Consistent with this
conclusion, a recent study showed that 7 of 7 (100%) cases of MDS arising in the setting of SDS carried
TP53 mutations.  However, because nearly all of the older patients with SDS had at least 1 TP53
mutation, other mutations, including mutations of the residual TP53 allele, are likely to be required for
leukemic transformation. The predictive value of clonal hematopoiesis due to TP53 mutations for the
development of MDS/AML in patients with SDS is currently unclear. However, 8 of 10 (80%) of our SDS
patients >10 years had at least 1 TP53 mutation. Thus, it is unlikely that the simple presence of TP53
mutations in blood/bone marrow will be a useful biomarker for the development of MDS/AML in these
patients. Whether the number of TP53 mutations, maximum variant allele fraction, or increase in TP53
allele burden over time is predictive will require prospective longitudinal studies.
We confirm prior studies showing a high incidence of CSF3R truncation mutations in patients with
SCN.  The truncated G-CSF receptor, although remaining dependent on G-CSF, transmits a
sustained, increased signal in response to G-CSF.  Expression of the truncated G-CSF receptor confers
a competitive advantage to HSCs in mice that is dependent on chronic G-CSF treatment.  Together, these
observations suggest that the very high level of G-CSF present in patients (through either endogenous
production or pharmacologic administration) is driving the expansion of HSPCs carrying CSF3R
mutations. Of note, no increase in clonal hematopoiesis due to other gene mutations was observed,
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demonstrating the highly selective nature of CSF3R-dependent clonal expansion in SCN. There is
evidence that CSF3R mutations contribute to the development of MDS/AML. A study showed that 13 of
18 (72%) patients with SCN who developed MDS/AML carried CSF3R mutations, compared with 43 of
125 (34%) without MDS/AML.  Moreover, truncation mutations of Csf3r cooperate with the PML-RAR
oncogene to induce AML in mice.  On the other hand, there are reports of MDS/AML arising in patients
with SCN prior to the availability of G-CSF.  The predictive value of CSF3R mutations in patients
with SCN for MDS/AML is uncertain. Our study does not resolve this issue, because only 2 patients in our
SCN cohort are known to have developed MDS/AML. Of note, prior studies show that CSF3R mutations
can persist for many years (and occasionally disappear) without developing MDS/AML in some patients
with SCN.  A recent report showed that mutations of RUNX1 were present in the majority (64.5%) of
patients with SCN who developed MDS or AML.  Interestingly, we identified no RUNX1 mutations in
our SCN cohort, which includes 2 patients who later developed AML. This is consistent with the
conclusion by Skokowa et al that RUNX1 mutations are a late step in leukemic transformation in patients
with SCN.
Our study has several limitations. Most importantly, the number of samples in which HSPC mutation
burden was determined, especially for SDS, was small. Only a minority of SDS samples generated
hematopoietic colonies of sufficient size for analysis, and it is not clear whether these cases are
representative of SDS in general. Our studies of clonal hematopoiesis were limited to a panel of 46 genes;
it is possible that mutations in other genes contribute to clonal hematopoiesis in congenital neutropenia.
In summary, our data suggest that both HSPC–cell-intrinsic and non–cell-intrinsic changes may determine
the competitive fitness of individual HSPCs. In the case of SCN, the persistently high levels of G-CSF
drive the expansion of HSPCs carrying mutations of CSF3R. In SDS, impaired ribosome biogenesis
induces p53-mediated growth inhibition and drives expansion of HSPCs carrying TP53 mutations. It is
likely that additional stressors may influence the development of clonal hematopoiesis. For example, a
recent study reported that exposure to chemotherapy results in a higher incidence of clonal hematopoiesis
carrying TP53 or PPM1D mutations.  Identifying cell-intrinsic and non–cell-intrinsic stressors that shape
the expansion of HSPCs may provide novel insights into the pathogenesis of AML or MDS.
Supplementary Material
The online version of this article contains a data supplement.
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Figure 1.
Hematopoietic progenitor mutation burden. (A) Experimental schema. CD34  CD38  lineage  cells from blood (Nm1,
Nm4, and cord blood) or bone marrow were sorted 1 cell per well and expanded on stromal support for 2 to 4 weeks.
Exome sequencing was performed on 4 hematopoietic progenitor clones isolated from 6 healthy donors, 3 cord blood, 11
SCN, or 2 SDS patients. Somatic mutations were identified by comparison with exome sequence data from matched
unfractionated blood or bone marrow leukocytes. (B) The number of somatic SNVs per exome for each clone. (C) The
average number of somatic SNVs per hematopoietic progenitor exome vs age at sample collection. (D) The average
number of somatic SNVs per exome. The mean ± standard error of the mean is shown. BM, bone marrow; HPC,
hematopoietic progenitor cell; ND, not determined; NM, healthy volunteers.
+ − −
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Table 1.
Demographic and disease characteristics HPC mutation burden cohort
Characteristic Normal (N = 6) SCN (N = 11) SDS (N = 2)
Age, y
 Mean ± SD 17.7 ± 4.4 16.6 ± 7.9 7.0 ± 7.1
 Median (range) 20 (9-20) 15.5 (6-36) 7.0 (2-12)
Female sex, n (%) 2 (33.3) 5 (45.4) 1 (50)
G-CSF treatment, n (%) 0 (0) 10 (100) 0 (0)
ANC per mm
 Mean ± SD na 62 ± 99 1170 ± 1198
 Median (range) na 0 (0-300) 1170 (330-2020)
ELANE mutation, n (%) na 10 (100) na
SBDS mutation, n (%) na na 2 (100)
ANC obtained prior to G-CSF therapy is shown. Percentage of patients with germ line heterozygous ELANE or
biallelic SBDS mutations is shown.
na, not available; SD, standard deviation.
Data not available for 1 patient with SCN.
Data not available for 2 patients with SCN.
Data not available for 1 patient with SCN.
*
3†
‡
*
†
‡
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Table 2.
Demographic and disease characteristics clonal hematopoiesis cohort
Characteristic Normal (N = 17) Cyclic (N = 13) SCN (N = 40) SDS (N = 27)
Age, y
 Mean ± SD 17.2 ± 10.1 24.5 ± 14.1 11.6 ± 10.3 7.9 ± 5.0
 Median (range) 17 (4-34) 26 (3-47) 10 (0.25-45) 6.3 (2-19)
Female sex, n (%) 8 (47.0) 4 (30.7) 23 (57.5) 11 (37.9)
G-CSF treatment, n (%) 0 (0) 10 (100) 38 (100) 10 (40)
ANC per mm
 Mean ± SD na 613 ± 554 140 ± 150 1080 ± 1070
 Median (range) na 400 90 (0-650) 770 (0-4490)
 ELANE mutation, n (%) na 9 (100) 39 (100) na
 SBDS mutation, n (%) na na na 27 (100)
 Allogenic stem cell transplant, n (%) na 1 (7.6%) 10 (25%) 1 (3.7)
 AML or MDS, n (%) na 0 (0) 2 (5.0%) 0 (0)
Data not available for 3 patients with cyclic neutropenia, 2 patients with SCN, and 2 patients with SDS.
ANC obtained prior to G-CSF therapy is shown. Data not available for 8 patients with cyclic neutropenia and 3
patients with SCN.
Percentage of patients with germ line heterozygous ELANE or biallelic SBDS mutations is shown. Data not available
for 4 patients with cyclic neutropenia and 1 patient with SCN.
Subsequent development of AML or MDS. No patient had MDS or AML at the time of sample analysis.
*
3†
‡
§
*
†
‡
§
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Figure 2.
Open in a separate window
Clonal hematopoiesis with CSF3R mutations. (A) Percentage of cases with clonal hematopoiesis due to any gene
mutation. (B) Age of individuals with or without clonal hematopoiesis due to any gene mutation. (C) Percentage of cases
with clonal hematopoiesis due to CSF3R mutations. ***P = .003 compared with healthy donors. (D) Percentage of cases
with clonal hematopoiesis due to mutations in genes besides CSF3R. (E) Age of patients with SCN based on the number
of CSF3R mutations. (F) The CSF3R mutations, with the number of times the mutation was seen in parentheses. (G) ANC
prior to G-CSF treatment. (H) The median G-CSF dose. The mean ± standard deviation is shown.
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Figure 3.
Clonal hematopoiesis with TP53 mutations. (A) Percentage of cases with clonal hematopoiesis due to TP53 mutations.
(B) Percentage of cases with clonal hematopoiesis due to mutations in genes besides TP53. ****P < .001 compared with
healthy donors. (C) Number of TP53 mutations per patient with SDS vs age. (D) Variant allele frequency (VAF) for
R249Q TP53 in serial bone marrow samples obtained for patient SDS34. (E) The TP53 mutations, with the number of
times the mutation was seen in parentheses. (F) Number of patients with severe neutropenia (ANC < 500 per mm ),
mild/moderate neutropenia (ANC 500-1500 per mm ), or no neutropenia. (G) Number of patients with anemia. (H)
Number of patients with thrombocytopenia. a.a., amino acid; n.t., nucleotide; pos, position.
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